Search Within

Jaclyn Frances Hechtman

  1. "Lu Wang"
Formats
  1. Journal Article (6)
Groups
  1. Department of Medicine (6)
  2. Department of Pathology and Laboratory Medicine (6)
  3. GSK Faculty (6)
  4. Human Oncology and Pathogenesis Program (6)
  5. Solid Tumor Oncology Division (6)
  6. Tow Center for Developmental Oncology (TCDO) (5)

More Groups

People
  1. Lu Wang (6)
  2. Marc Ladanyi (5)
  3. Rona Yaeger (4)
  4. Ahmet Zehir (3)
  5. David Hyman (3)
  6. Efsevia Vakiani (3)

More People

Years
  1. 2017 (2)
  2. 2016 (4)
Publications
  1. Molecular Cancer Research (2)
  2. Annals of Oncology (1)
  3. Cancer Research (1)
  4. Clinical Cancer Research (1)
  5. Oncotarget (1)
Publishers
  1. American Association for Cancer Research (4)
  2. Impact Journals (1)
  3. Oxford University Press (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition
    Journal Article

    Yaeger, R.; Yao, Z.; Hyman, D. M.; Hechtman, J. F.; Vakiani, E.; Zhao, H.; Su, W.; Wang, L.; Joelson, A.; Cercek, A.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Chromosome 20q amplification defines a subtype of microsatellite stable, left-sided colon cancers with wild-type RAS/RAF and better overall survival
    Journal Article

    Ptashkin, R. N.; Pagan, C.; Yaeger, R.; Middha, S.; Shia, J.; O'Rourke, K. P.; Berger, M. F.; Wang, L.; Cimera, R.; Wang, J.; more...
    Molecular Cancer Research (2017)

    Fulltext@MSK | Save
  • Recurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma
    Journal Article

    Javier, B. M.; Yaeger, R.; Wang, L.; Sanchez-Vega, F.; Zehir, A.; Middha, S.; Sadowska, J.; Vakiani, E.; Shia, J.; Klimstra, D.; more...
    Oncotarget (2016)

    Fulltext@MSK | Save
  • A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer
    Journal Article

    Drilon, A.; Somwar, R.; Wagner, J. P.; Vellore, N. A.; Eide, C. A.; Zabriskie, M. S.; Arcila, M. E.; Hechtman, J. F.; Wang, L.; Smith, R. S.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF
    Journal Article

    Hechtman, J. F.; Zehir, A.; Yaeger, R.; Wang, L.; Middha, S.; Zheng, T.; Hyman, D. M.; Solit, D.; Arcila, M. E.; Borsu, L.; more...
    Molecular Cancer Research (2016)

    Fulltext@MSK | Save